Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

EMA Opens Consultation on Draft Guideline for Predictive Biomarker Assays in Medicine Development

The EMA is taking comments until 31 March 2027 on a draft guideline setting evidence expectations for biomarker tests that select patients for medicines.

Published 19 Nov 2026· 7 minute read
Stained histology slides from a pathology laboratory laid out in rows on a wooden rack, tissue sections prepared for microscope examination
Photo: myself ( Alex_brollo ) / Wikimedia Commons, CC BY-SA 3.0 (cropped). Source · Licence

The European Medicines Agency opened public consultation on 9 November 2026 on a draft guideline setting out what developers of biomarker-guided medicines should show about the biomarker test used to select patients. The Committee for Medicinal Products for Human Use adopted the draft on 3 November, and comments are accepted until 31 March 2027, which matters to trial sponsors, academic trial units and research offices.

What happened

The EMA published the draft “Guideline on predictive biomarker assays in the context of medicinal product lifecycle” (reference EMA/CHMP/800914/2016) after the CHMP adopted it on 3 November 2026, according to the draft document. The EMA’s guideline page lists the draft as the current version, first published on 9 November 2026, with the consultation running from 9 November 2026 to 31 March 2027. Comments are submitted through an EUSurvey form linked from that page.

The draft replaces the concept paper of the same reference number, which went through public consultation from 28 July to 15 November 2017. Trade coverage on 12 November, including a RAPS Euro Roundup and a Syenza News report, picked up the publication within days.

The 26-page draft describes the information needed for a marketing authorisation application for a biomarker-guided medicine and for later post-authorisation applications such as indication extensions. It also gives general recommendations on how biomarker and assay information should appear in the Summary of Product Characteristics (SmPC).

Key details of the draft

The EMA states that the efficacy and safety of a biomarker-guided medicine rely on an analytically robust, reliable and clinically useful assay. Where that assay fits the definition in the In Vitro Diagnostic Regulation (IVDR), it may be a companion diagnostic. The draft is aimed mainly at medicinal product developers, but the EMA notes that it may also help diagnostic manufacturers who work with them, because it covers the interface with the IVDR.

Topic in the draft What the draft says
Context of use Defined as the proposed indication, the intended purpose of the in vitro diagnostic, the target population and the conditions for use; supporting data should be submitted with the application.
Pre-screening Biomarker-based pre-screening (selection) should generally be avoided because a local test can introduce bias; developers are encouraged to test a proportion of local test-negative samples with the candidate companion diagnostic.
Missing data Eligibility criteria should generally require baseline biomarker data, exceptions must be well justified, and statistical methods for missing biomarker data should be pre-specified in the analysis plan.
Testing sites In decentralised testing the same assay at all sites is strongly recommended; for complex platforms such as cut-slide immunohistochemistry assays, centralised testing is generally recommended.
Clinical validation Shown through a differential treatment effect by biomarker status, meaning a biomarker-by-treatment interaction, which generally needs data from the overall patient population.
Bridging studies Needed when different assays are used, for example after major assay changes during a pivotal trial or for a follow-on companion diagnostic, to show that the biomarker-selected populations are highly similar.
SmPC Where an indication or contraindication depends on the biomarker, a reference to it is mandatory in section 4.1 or 4.3; related information is foreseen in sections 4.1, 4.2, 4.3, 4.4, 4.8 and 5.1 as relevant.
Post-approval Remaining uncertainties about biomarkers or assay performance at authorisation may need to be addressed after approval, depending on their effect on the benefit-risk profile.

The Regulatory Affairs News summary of the draft lists the same building blocks: defining context of use, analytical and clinical validation, sample and data management, bridging of platform or cut-off changes, comparable performance across centralised or decentralised sites, and keeping assay information current in the SmPC after approval, as reported in its review of the EMA drafts.

Background and context

Predictive biomarker-guided medicines link the clinical use of a medicine to a test that identifies patients most likely to benefit or at increased risk of serious adverse reactions. The EMA describes this as one of the most widespread applications of personalised medicine in Europe. The draft sets out the legal split behind it: medicines and in vitro diagnostics are regulated under separate frameworks. Under Regulation (EU) 2017/746, a companion diagnostic is placed in risk class C or higher and needs certificates from a notified body, and the notified body must consult a medicines authority as part of certification.

The draft states that approval of the medicine is independent of the companion diagnostic certification, and that during a marketing authorisation procedure the medicines authority does not assess the IVDR conformity of the assay used in pivotal studies. It evaluates instead whether the assay was appropriate for selecting patients and whether the analytical validation supports the benefit-risk assessment. The guideline excludes in vivo diagnostics, the classification of in vitro diagnostics, requirements for diagnostics in clinical trial approval under the Clinical Trials Regulation, and conformity assessment under the IVDR.

The consultation was one of several EMA drafts released in the same period. Coverage by RAPS and Regulatory Affairs News also noted a draft guideline on reproductive and developmental risks of medicines, with feedback due by 28 February 2027, and the MHRA’s guidance on non-OECD nonclinical data for UK clinical trial applications. For readers new to the framework, the CASRAI guides on IVDR classification and notified body requirements and on what counts as an in vitro diagnostic explain the device side, and EMA versus FDA regulatory pathways sets the European route beside the US one.

Reaction and coverage

Trade coverage has so far been descriptive. RAPS summarised the draft as covering the scientific requirements for developing and validating predictive biomarkers and companion assays, the evidence to generate through clinical development, and possible post-approval follow-up to resolve uncertainties present at authorisation. Syenza News reported the adoption and consultation dates and quoted the EMA’s description of predictive biomarker-guided medicines as among the most widely implemented regulatory concepts of personalised medicine in Europe. Regulatory Affairs News described the primary audience as medicinal product developers with support for collaboration with diagnostic and companion diagnostic manufacturers.

What it means for researchers, universities and research offices

Most of the draft addresses sponsors, but its expectations land on the people who design and run trials. Academic sponsors and investigator-initiated trial units that use a biomarker to select patients should read the sections on context of use, pre-screening and missing data against their protocol templates. The draft expects baseline biomarker results to be an inclusion requirement in general, so eligibility criteria, sample collection schedules and the statistical analysis plan need to anticipate how biomarker status will be recorded and how gaps will be handled.

Laboratory arrangements are the second pressure point. A trial that relies on local hospital laboratories needs a plan for showing comparable assay performance across sites, and the draft points to bridging studies and round-robin testing as options. It also notes that samples from patients excluded because of their biomarker status may be valuable for future bridging studies, which bears on biobanking consent and storage decisions made at the start of a trial.

Research offices and regulatory affairs staff should also track the interface between the medicines and device frameworks. Because the diagnostic route runs through a notified body, academic groups co-developing an assay with a medicine face two separate procedures; the CASRAI guide to notified body designation and audits under MDR and IVDR covers that side. For wider device guidance, see the MDCG guidance overview, since the draft cites several Medical Device Coordination Group documents.

What happens next

The consultation is open from 9 November 2026 to 31 March 2027, and the draft does not give a date for a final version. Institutions that want to comment, for example on how the requirements apply to investigator-initiated trials, can use the EUSurvey form on the EMA guideline page. Sponsors planning marketing authorisation applications for biomarker-guided medicines can use the period to compare their assay validation plans against the draft’s sections on analytical validation, clinical validation and bridging.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →